16S rRNA and Metagenomics Combined with UPLC-Q/TOF-MS Metabolomics Analysis Reveals the Potential Mechanism of Radix Astragali Against Hyperuricemia in Mice

Purpose This study aimed to investigate the underlying treatment mechanism of Radix Astragali (RA) in hyperuricemia from the perspective of microbiota and metabolomics. Methods We used potassium oxyazinate (PO) to induce hyperuricemia mice, and we determined serum alanine aminotransferase/aspartate aminotransferase (ALT/AST), xanthine oxidase (XOD), creatinine (CRE), uric acid (UA), blood urea nitrogen (BUN) levels, liver XOD levels and assessed the kidney tissue histopathology. The therapeutic mechanism of RA in hyperuricemic mice was studied by 16S rRNA, metagenomic sequencing and metabolomics. Results Our research showed that RA has therapeutic effect in hyperuricemia mice, such as slow the weight loss, repair kidney damage, and downregulate serum UA, XOD, CRE, ALT/AST, BUN, and liver XOD levels. RA restored the disturbance structure of the microbiota in hyperuricemia mice by increasing the relative abundances of beneficial bacteria (Lactobacillaceae and Lactobacillus murine) but decreasing the relative abundances of pathogenic bacteria (Prevotellaceae, Rikenellaceae and Bacteroidaceae). Meanwhile, we found that RA directly regulated the metabolic pathway (such as linoleic acid metabolism and glycerophospholipid metabolism) and indirectly regulated bile acid metabolism by mediating microbiota to ameliorate metabolic disorders. Subsequently, there was a robust correlation between specific microbiota, metabolites and the disease index. Conclusion The ability of RA to protect mice against hyperuricemia is strongly linked to the microbiome-metabolite axis, which would provide evidence for RA as a medicine to prevent or treat hyperuricemia.

[1]  Xu Zhao,et al.  Bioactivity and Component Analysis of Water Extract of Sophora japonica against Hyperuricemia by Inhibiting Xanthine Oxidase Activity , 2022, Foods.

[2]  Zhaofeng Zhang,et al.  Multi-omics analysis reveals therapeutic effects of Bacillus subtilis-fermented Astragalus membranaceus in hyperuricemia via modulation of gut microbiota. , 2022, Food chemistry.

[3]  Wenwen Zhang,et al.  Multi metabolomics-based analysis of application of Astragalus membranaceus in the treatment of hyperuricemia , 2022, Frontiers in Pharmacology.

[4]  Xiaoyu Chen,et al.  Lacticaseibacillus rhamnosus Fmb14 prevents purine induced hyperuricemia and alleviate renal fibrosis through gut-kidney axis. , 2022, Pharmacological research.

[5]  Y. Wu,et al.  Probiotics Interact With Lipids Metabolism and Affect Gut Health , 2022, Frontiers in Nutrition.

[6]  Lvqin He,et al.  The Microbiota and It’s Correlation With Metabolites in the Gut of Mice With Nonalcoholic Fatty Liver Disease , 2022, Frontiers in Cellular and Infection Microbiology.

[7]  Jeong Seop Park,et al.  Substance P Hinders Bile Acid-Induced Hepatocellular Injury by Modulating Oxidative Stress and Inflammation , 2022, Antioxidants.

[8]  J. Suh,et al.  Potential Probiotic Lacticaseibacillus paracasei MJM60396 Prevents Hyperuricemia in a Multiple Way by Absorbing Purine, Suppressing Xanthine Oxidase and Regulating Urate Excretion in Mice , 2022, Microorganisms.

[9]  Yu He,et al.  A critical review of Astragalus polysaccharides: From therapeutic mechanisms to pharmaceutics. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  Y. Takeishi,et al.  Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial , 2021, The Journal of international medical research.

[11]  Lin Tang,et al.  Structural and Functional Alterations of Gut Microbiota in Males With Hyperuricemia and High Levels of Liver Enzymes , 2021, Frontiers in Medicine.

[12]  F. Tomás-Barberán,et al.  Jaboticaba (Myrciaria jaboticaba) powder consumption improves the metabolic profile and regulates gut microbiome composition in high-fat diet-fed mice. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  Bing Zhang,et al.  Metabolome-wide association study of serum exogenous chemical residues in a cohort with 5 major chronic diseases. , 2021, Environment international.

[14]  A. Ajayi,et al.  Omega-3 fatty acid rescues ischaemia/perfusion-induced testicular and sperm damage via modulation of lactate transport and xanthine oxidase/uric acid signaling. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[15]  Shuqin Xie,et al.  The association between urate‐lowering therapies and treatment‐related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta‐analysis of randomized trials , 2021, Pharmacotherapy.

[16]  Q. Ma,et al.  High-Throughput Untargeted Serum Metabolomics Analysis of Hyperuricemia Patients by UPLC-Q-TOF/MS , 2021, Evidence-based complementary and alternative medicine : eCAM.

[17]  Xiaosong Hu,et al.  The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies , 2021, Critical reviews in food science and nutrition.

[18]  A. Dzutsev,et al.  Transkingdom interactions between Lactobacilli and hepatic mitochondria attenuate western diet-induced diabetes , 2021, Nature Communications.

[19]  Changtao Jiang,et al.  The role of the gut microbiome and its metabolites in metabolic diseases , 2020, Protein & Cell.

[20]  P. Wiland,et al.  Pathophysiology of hyperuricemia and its clinical significance – a narrative review , 2020, Reumatologia.

[21]  L. Jacobsson,et al.  Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors , 2020, Nature Reviews Rheumatology.

[22]  Li Lin,et al.  Evodiamine has therapeutic efficacy in ulcerative colitis by increasing Lactobacillus acidophilus levels and acetate production. , 2020, Pharmacological research.

[23]  K. Śliżewska,et al.  The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome , 2020, Nutrients.

[24]  Yi-Jun Zheng,et al.  A Review of the Pharmacological Action of Astragalus Polysaccharide , 2020, Frontiers in Pharmacology.

[25]  C. Deming,et al.  Preventing dysbiosis of the neonatal mouse intestinal microbiome protects against late-onset sepsis , 2019, Nature Medicine.

[26]  Yuehua Jiang,et al.  Study on the Antihypertensive Mechanism of Astragalus membranaceus and Salvia miltiorrhiza Based on Intestinal Flora-Host Metabolism , 2019, Evidence-based complementary and alternative medicine : eCAM.

[27]  F. Parveen,et al.  An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases , 2019, International journal of molecular sciences.

[28]  C. Pepine,et al.  The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease , 2018, Nature Reviews Nephrology.

[29]  Jian Zhang,et al.  Effects of Qijian mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology , 2018, Pharmacological research.

[30]  Xiao-hong Liu,et al.  Relationships of Inflammatory Factors and Risk Factors with Different Target Organ Damage in Essential Hypertension Patients , 2017, Chinese medical journal.

[31]  Huawei Zeng,et al.  Colonic Inflammation Accompanies An Increase of β‐Catenin Signaling and Lachnospiraceae/Streptococcaceae in the Hind Gut of High‐Fat Diet‐Fed Mice , 2016, The Journal of nutritional biochemistry.

[32]  R. Liu,et al.  Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis , 2015, BioMed research international.

[33]  Chunming Yong,et al.  Analysis of intestinal flora in patients with hyperuricemia in Qindao District , 2014 .

[34]  L. Goldstein,et al.  Chronic kidney disease and stroke. , 2014, Advances in chronic kidney disease.

[35]  C. Hsieh,et al.  Chronic kidney disease and stroke , 2014, The Lancet Neurology.

[36]  Keishi Kameyama,et al.  Intestinal Colonization by a Lachnospiraceae Bacterium Contributes to the Development of Diabetes in Obese Mice , 2014, Microbes and environments.

[37]  Yun-Hae Lee,et al.  Characterization of an Anti-gout Xanthine Oxidase Inhibitor from Pleurotus ostreatus , 2014, Mycobiology.

[38]  B. Kuster,et al.  High-fat diet alters gut microbiota physiology in mice , 2013, The ISME Journal.

[39]  J. Crane,et al.  Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenic Escherichia coli , 2013, Gut microbes.

[40]  Duolong Di,et al.  Metabolite target analysis of human urine combined with pattern recognition techniques for the study of symptomatic gout. , 2012, Molecular bioSystems.

[41]  Mahmud Tareq Hassan Khan,et al.  Tyrosinase inhibition studies of cycloartane and cucurbitane glycosides and their structure-activity relationships. , 2006, Bioorganic & medicinal chemistry.

[42]  F. Lioté Hyperuricemia and gout , 2003, Current rheumatology reports.

[43]  OUP accepted manuscript , 2022, Journal of Pharmacy and Pharmacology.

[44]  Guang Shan,et al.  Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF‐&kgr;B in vivo and in vitro , 2017, International immunopharmacology.

[45]  K. James Drug design , 1992, Nature.

[46]  D. Levinson,et al.  Origin and extrarenal elimination of uric acid in man. , 1975, Nephron.